000			01867cam a2200241 4500500
005			20250112030512.0
041			_afre
042			_adc
100	1	0	_aMoukafih, Badreddine _eauthor
700	1	0	_a Bandadi, Fatimazahra _eauthor
700	1	0	_a El Marrakchi, Soufiane _eauthor
700	1	0	_a Bennani, Ismail _eauthor
700	1	0	_a Nchinech, Nawal _eauthor
700	1	0	_a Hafidi, Youssef _eauthor
700	1	0	_a Achour, Sanae _eauthor
700	1	0	_a El Kartouti, Abdeslam _eauthor
245	0	0	_aDrug-induced hepatitis: Epidemiological, clinical, diagnostic, and pathophysiological aspects
260			_c2023.
500			_a34
520			_aAlthough drug-induced liver injury is a rare clinical event, it causes significant morbidity and mortality, making it the leading cause of acute liver failure. The predominant clinical presentation is acute hepatitis and/or cholestasis, although almost any clinical pathological pattern of acute or chronic liver disease can occur. The pathogenesis of drug-induced liver disease usually involves the drug or metabolites that directly affect cellular biochemistry or elicit an immune response. Susceptibility to drug-induced hepatotoxicity is also influenced by genetic and environmental risk factors. Unpredictable, low-frequency, and idiosyncratic reactions often occur in the context of high levels of mild asymptomatic liver damage and, although difficult to predict, can be detected by monitoring serum alanine aminotransferase levels. The development of various drug-injury networks has played a key role in expanding our knowledge of liver injury associated with drugs, herbs, and dietary supplements.
786	0		_nCahiers Santé Médecine Thérapeutique | 32 | 5 | 2023-09-01 | p. 216-222 | 2780-8858
856	4	1	_uhttps://shs.cairn.info/journal-cahiers-sante-medecine-therapeutique-2023-5-page-216?lang=en
999			_c152431 _d152431